Introduction of MMF in conjunction with stepwise reduction of calcineurin inhibitor in stable liver transplant patients with renal dysfunction

International Immunopharmacology

Volumn 5, Issue 1, 2005, Pages 141-146

  Kornberg, Arno ^a   Küpper, Bernadette ^a   Hommann, Merten ^a   Scheele, Johannes ^a  

^a FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

Author keywords

Calcineurin inhibitor; Liver transplantation; Mycophenolat mofetil; Renal dysfunction

Indexed keywords

CALCINEURIN INHIBITOR; CELL CEPT; CREATININE; CYCLOSPORIN A; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS; UNCLASSIFIED DRUG; UREA;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIARRHEA; DIASTOLIC BLOOD PRESSURE; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG SCREENING; DRUG WITHDRAWAL; FEMALE; GENERAL CONDITION IMPROVEMENT; GRAFT REJECTION; HEALTH HAZARD; HUMAN; IMMUNE SYSTEM; KIDNEY FUNCTION; LEUKOPENIA; LIVER GRAFT; LOW DRUG DOSE; MALE; NAUSEA; NEPHROTOXICITY; PRIORITY JOURNAL; PRURITUS; SYSTOLIC BLOOD PRESSURE;

ADULT; AGED; BLOOD PRESSURE; CALCINEURIN; CARDIOVASCULAR DISEASES; CHOLESTEROL; CREATININE; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY DISEASES; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; RISK FACTORS; UREA; URIC ACID;

EID: 10344250408     PISSN: 15675769     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.intimp.2004.09.018     Document Type: Article

References (18)

1. A. Jain, J. Reyes, R. Kashyap, S.F. Dodson, A.J. Demetris, and K. Ruppert Long-term survival after liver transplantation in 4000 consecutive patients at a single center Ann. Surg. 232 2000 490
2. The US Multicenter FK506 Liver Study Group A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression in liver transplantation N. Engl. J. Med. 331 1994 1110
3. J.M. Campistol, and S.H. Sacks Mechanisms of nephrotoxicity Transplantation 69 2000 5 (Suppl)
4. A.J. Olyaei, A.M. deMattos, and W.M. Bennett A practical guide to the management of hypertension in renal transplant recipients Drugs 58 1999 1011
5. J. McCauley, D.H. Van Thiel, T.E. Starzl, and J.B. Puschett Acute and chronic renal failure in liver transplantation Nephron 55 1990 121
6. R. Wiesner, J. Rabkin, G. Klintmalm, S. McDiarmid, A. Langnas, and J. Punch A randomized double-blind comparative study of mycophenolate mofetil and azathioprine in combination with cyclosporine and corticosteroids in primary liver transplant recipients Liver Transpl. 7 2001 442
7. M.F. Herbert, N.L. Ascher, J.R. Lake, J. Emond, B. Nikolai, and T.J. Linna Four-year follow-up of mycophenolat mofetil for graft rescue in liver allograft recipients Transplantation 67 1999 707
8. S.F. Stewart, M. Hudson, D. Talbot, D. Manas, and C.P. Day Mycophenolate mofetil monotherapy in liver transplantation Lancet 357 2001 609
9. H.J. Schlitt, A. Barkmann, K.H. Boker, H.H. Schmidt, N. Emmanouilidis, and J. Rosenau Replacement of calcineurin inhibitors with mycophenolate mofetil in liver-transplant patients with renal dysfunction: a randomised controlled study Lancet 357 2001 587
10. T.A. Gonwa, M.L. Mai, L.B. Melton, S.R. Hays, R.M. Goldstein, and M.F. Levy End-stage renal disease (ESRD) after orthotopic liver transplantation (OLTX) using calcineurin-based immunotherapy: risk of development and treatment Transplantation 72 2001 1934
11. N.C. Fisher, P.G. Nightingale, B.K. Gunson, G.W. Lipkin, and J.M. Neuberger Chronic renal failure following liver transplantation: a retrospective analysis Transplantation 66 1998 59
12. M.E. Falkenhain, F.G. Cosio, and D.D. Sedmak Progressive histologic inclosporine Transplantation 62 1996 364
13. A.C. Allison, and E.M. Eugui Mycophenolate mofetil and its mechanisms of action Immunopharmacology 47 2000 85
14. W.J. Sandborn, J.E. Hay, M.K. Porayko, G.J. Gores, J.L. Steers, and R.A. Krom Cyclosporine withdrawal for nephrotoxicity in liver transplant recipients does not result in sustained improvement in kidney function and causes cellular and ductopenic rejection Hepatology 19 1994 925
15. J.I. Herrero, J. Quiroga, B. Sangro, M. Girala, N. Gomez-Manero, and F. Pards Conversion of liver transplant recipients on cyclosporine with renal impairment to mycophenolate mofetil Liver Transpl. Surg. 5 1999 414
16. M. Cantarovich, G.N. Tzimas, J. Barkun, M. Deschenes, E. Alpert, and J. Tchervenkov Efficacy of mycophendate mofetil combined with very low-dose cyclosporine microemulsion in long-term liver-transplant patients with renal dysfunction Transplantation 15 2003 98
17. A. Barkmann, B. Nashan, H.H. Schmidt, K.H. Boker, N. Emmanouilidis, and J. Rosenau Improvement of acute and chronic renal dysfunction in liver transplant patients after substitution of calcineurin inhibitors by mycophenolate mofetil Transplantation 15 69 2000 1886
18. A.A. Hollander, J.L. van Saase, A.M. Kootte, W.T. van Dorp, H.J. van Bockel, and L.A. van Es Beneficial effects of conversion from cyclosporin to azathioprine after kidney transplantation Lancet 11 345 1995 610